Format

Send to

Choose Destination
Am J Obstet Gynecol. 2000 Aug;183(2):511-2.

Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy.

Author information

1
Service de Gynécologie et Obstetrique, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Abstract

Polychemotherapy including idarubicin was administered during the second trimester to treat acute lymphoblastic leukemia. The infant delivered at 28 weeks' gestation had acute cardiac failure attributed to the cardiotoxic effect of idarubicin. Cardiotoxicity may be caused by idarubicin's biophysical properties that facilitate its transplacental passage. Idarubicin should be used with extreme caution during pregnancy.

PMID:
10942501
DOI:
10.1067/mob.2000.105964
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center